Trinity Biotech PLC 6-K, filed Jul 11, 2024
Trinity Biotech PLC (TRIB)
6-K
2024-07-11
For: 2024-07-11
View Original
Added on
April 12, 2026
About this 6-K
Trinity Biotech PLC filed this 6-K on July 11, 2024.
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2024
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, County Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070) and Registration Statements on Form
F-3 (File Nos. 333-264992, 333-267160, 333-279017 and 333-280391).
EXPLANATORY NOTE
On July 9, 2024 the Company announced the appointment of Louise Tallon as Chief Financial Officer (“CFO”). Louise will join Trinity Biotech in August 2024. Des Fitzgerald, who
has acted as interim CFO since December 2023 will continue as interim CFO until late July 2024.
Additionally, Mr. Simon Dunne, Chief Accounting Officer of Trinity Biotech, will be leaving the Company in August 2024. His role as Chief Accounting Officer will also be assumed
by Ms. Tallon. A copy of the press release is furnished herewith as Exhibit 99.1.
EXHIBIT INDEX
|
Exhibit
|
|
Description
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
TRINITY BIOTECH PLC
|
|||
|
Trinity Biotech plc
|
|||
|
(Registrant)
|
|||
|
By:
|
/s/ Des Fitzgerald
|
||
|
Des Fitzgerald
|
|||
|
Interim Chief Financial Officer
|
|||
Date: July 11, 2024
Exhibit 99.1
| Contact: | Trinity Biotech plc | LifeSci Partners, LLC |
| Des Fitzgerald | Eric Ribner | |
| (353)-1-2769800 | (1)-646-751-4363 | |
| E-mail: investorrelations@trinitybiotech.com |
Trinity Biotech Announces Appointment of A New CFO
DUBLIN, Ireland (July 09, 2024)…. Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions,
including wearable biosensors, today announces the appointment of Louise Tallon as Chief Financial Officer (“CFO”). Louise will join Trinity Biotech in August 2024. Des Fitzgerald, who has acted as interim CFO since December 2023 will continue as
interim CFO until late July 2024.
Commenting on the appointment, John Gillard, CEO of Trinity Biotech plc, said “We are delighted to welcome Louise, who brings extensive experience in transformation and growth within a dynamic environment. This skill
set, combined with her extensive experience in the life sciences product commercialisation industry, will elevate the continued development of the organisation as we continue to deliver on our corporate strategy of delivering our comprehensive
transformation plan and introducing our next generation continuous glucose monitor, or CGM, to global markets. With the CFO transition we also reiterate our financial guidance and intend to achieve approximately $20 million of annualized run-rate
EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025.”
Louise Tallon responded, “I’m excited to join the Trinity Biotech team and look forward to contributing to its exciting vision to become a highly profitable organisation, intent on executing its development and launch of
a next generation CGM device.”
Louise is currently Head of Group Finance at Inizio, a leading global commercialisation partner in pharmaceuticals. Prior to this, she had a 16-year career with UDG Healthcare plc, where she held a number of senior
finance roles of increasing responsibility. Over her 19-year career in the life sciences industry, as a transformative leader, Louise has been at the forefront of adapting and evolving finance functions in a rapidly changing business landscape.
Louise trained as an accountant in KPMG, having received a BBS, Finance, Economics and Business in Trinity College Dublin.
Mr. Simon Dunne, Chief Accounting Officer of Trinity Biotech, will be leaving the Company in August 2024. His role as Chief Accounting Officer will also be assumed by Ms. Tallon. Trinity Biotech thanks both Des and Simon
for their many contributions to the Company and wishes them both all the best.
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited
to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity
Biotech claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterised by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of
similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on our purchase of the assets of
Waveform, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the
company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence
on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of
defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of
infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended
December 31, 2023 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not
undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires,
manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition
of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify
the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners
in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.